EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond Efficacy: Preclinical Validation and Translational Readiness of Recent Multimodal Photodynamic Nanoplatforms for Glioblastoma

Paweł Woźnicki iD, David Aebisher iD

International Journal of Molecular Sciences · 04.11.2026 · 27 (21) · 9878

DOI: 10.3390/ijms27219878 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.11.2026. Verfasst von Paweł Woźnicki und 1 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-310 Rzeszów, Poland. Hauptthemen laut MEDLINE: Glioblastoma, Photochemotherapy, Photosensitizing Agents, Nanoparticles. Die Arbeit nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multimodal photodynamic therapy (PDT)-based nanoplatforms are increasingly being developed for glioblastoma (GBM) to improve photosensitizer delivery, overcome tumor hypoxia, and combine PDT with complementary therapeutic mechanisms. However, promising antitumor activity does not necessarily translate into adequate preclinical validation or clinical readiness. This review critically evaluates recent studies published between January 2025 and August 2026, identified through PubMed, Scopus and Web of Science. Of 3617 records screened, 35 studies met the broader eligibility criteria for nanoparticle-mediated PDT in GBM, including 19 studies incorporating in vivo evaluation. Particular attention was given to the biological relevance of experimental models, survival assessment, biodistribution, pharmacokinetics, clearance, systemic and neurological safety, and platform-specific translational limitations. Orthotopic models were used in 16 of 19 in vivo studies, whereas immunocompetent and immunodeficient hosts were represented almost equally. Nevertheless, clinically challenging settings such as post-resection disease, acquired temozolomide resistance and recurrence after standard therapy were rarely reproduced. Quantitative pharmacokinetic and elimination data were limited, and fluorescence or elemental measurements frequently reflected individual platform components rather than intact nanostructures. Safety assessments were predominantly short-term and often focused on body weight, routine blood parameters and organ histology. Overall, the current evidence demonstrates substantial therapeutic innovation but also reveals a persistent gap between antitumor efficacy and translational validation. Future studies should prioritize clinically representative models, quantitative absorption, distribution, metabolism and excretion (ADME) characterization, long-term and neurological safety assessment, and comparisons with current standard-of-care treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaPhotochemotherapyPhotosensitizing AgentsNanoparticlesBrain NeoplasmsHumansAnimalsTranslational Research, Biomedical

Stichwörter der Autor:innen

biodistributionbiosafetyglioblastomamultimodal therapynanomedicinenanoplatformspharmacokineticsphotodynamic therapypreclinical modelstranslational readiness

Substanzen

Photosensitizing Agents

Autor:innen und Institutionen

  • Doctoral School, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-310 Rzeszów, Poland.
  • Department of Photomedicine and Physical Chemistry, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-310 Rzeszów, Poland.

ORCID-Profile: Paweł Woźnicki, David Aebisher

Zitieren

APA

Woźnicki, P., & Aebisher, D. (2026). Beyond Efficacy: Preclinical Validation and Translational Readiness of Recent Multimodal Photodynamic Nanoplatforms for Glioblastoma. International Journal of Molecular Sciences, 27(21), 9878. https://doi.org/10.3390/ijms27219878

Vancouver

Woźnicki P, Aebisher D. Beyond Efficacy: Preclinical Validation and Translational Readiness of Recent Multimodal Photodynamic Nanoplatforms for Glioblastoma. International Journal of Molecular Sciences. 2026;27(21):9878. doi:10.3390/ijms27219878

BibTeX
@article{Wonicki2026,
  author = {Woźnicki, Paweł and Aebisher, David},
  title = {Beyond Efficacy: Preclinical Validation and Translational Readiness of Recent Multimodal Photodynamic Nanoplatforms for Glioblastoma},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {9878},
  doi = {10.3390/ijms27219878}
}
Kostenlos starten →